Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 4/20 | 0.53 |
| ▸ | MAN2A1 | Q16706 | 2/20 | 0.46 |
| ▸ | MAN1B1 | Q9UKM7 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | RGS12 | O14924 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9729227 | 0.83 | AOC3 (0.55) | AOC3MAN2A1MAN1B1ADRA2CCHRM2 | |
| SCHEMBL9729078 | 0.82 | ALDH1A1 (0.47) | AOC3MAN2A1MAN1B1ADRA2CCHRM2 | |
| SCHEMBL9729435 | 0.81 | AOC3 (0.53) | AOC3MAN2A1MAN1B1ADRA2CCHRM2 | |
| SCHEMBL13990579 | 0.81 | CYP2D6 (0.58) | AOC3SIGMAR1ADRA2CCHRM2ADRA1A | |
| SCHEMBL11879421 | 0.81 | AOC3 (0.58) | AOC3MAN2A1MAN1B1ADRA2CCHRM2 | |
| SCHEMBL22461952 | 0.81 | CYP2D6 (0.58) | AOC3SIGMAR1ADRA2CCHRM2ADRA1A | |
| SCHEMBL9729205 | 0.81 | ALDH1A1 (0.46) | AOC3MAN2A1MAN1B1TSHRLMNA | |
| SCHEMBL9728882 | 0.81 | HPGD (0.49) | AOC3MAN2A1MAN1B1ADRA2CCHRM2 | |
| SCHEMBL9729125 | 0.81 | AOC3 (0.49) | AOC3MAN2A1MAN1B1ADRA2CCHRM2 | |
| SCHEMBL9728901 | 0.80 | ALDH1A1 (0.54) | AOC3MAN2A1MAN1B1ADRA2CCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2005-01-27 | — | — | US | claimed |
| EP-1457494-A1 | PROCESSES FOR PREPARATION OF SULPHOSTIN AND ITS ANALOGUES OR INTERMEDIATES THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2004-09-15 | — | — | EP | claimed |
| US-7531657-B2 | Method for preparing sulphostin and analogue thereof or preparation intermediate thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1457494-A1 | PROCESSES FOR PREPARATION OF SULPHOSTIN AND ITS ANALOGUES OR INTERMEDIATES THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | SOST, PTMS, FGF23 | AOC3 2624/4885MAN2A1 4362/4885MAN1B1 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.